Document is current

Any future updates will be listed below

Etanercept biosimilar (recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein) and methotrexate combination therapy in Chinese patients with moderate-to-severe plaque psoriasis: a multicentre, randomized, double-blind, placebo-controlled trial

Crossref DOI link: https://doi.org/10.1007/s00403-019-02024-6

Published Online: 2019-12-23

Published Print: 2020-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark